Is It OK For Pfizer To Pay For Reporters To Learn About Cancer?


By Betsy Raymond Stevenson, posted August 25, 2010

Actavis launches challenge to Pfizer drug


By Betsy Raymond Stevenson, posted October 2, 2009

pfizer_logo

Pipeline Expertise


By Betsy Raymond Stevenson, posted October 1, 2009

wsj

Context:

  • Raise awareness of Pfizer as a major innovator

Challenge:

  • Belief that real innovation mostly happens in small organizations

Solution:

  • Betsy’s long-standing relationships with the Wall Street Journal convinced them to send a reporter to meet the varenicline R&D team while this novel, first-in-class candidate was in Phase II trials

Result:

  • A major feature story in the Wall Street Journal on Pfizer’s innovative research

Pharmaceuticals Expertise


By Betsy Raymond Stevenson, posted October 1, 2009

aromasin RSHC_Pfizer

Context and Challenges:

  • Pfizer wanted to grow sales of its last-in-class breast cancer treatment Aromasin
    • Little awareness that Aromasin was the only drug in its class shown to improve survival
    • NICE about to pick only one of the drugs in this class for the UK formulary

Solution:

  • Met with marketing & medical teams to review study data and competitive environment
  • Created and conducted international media campaign on Aromasin’s unique benefit in class

Results:

  • Media campaign key to 30% year-end sales growth, per Pfizer US Director of Marketing
  • Aromasin selected for NICE formulary over competitors

ABOUT BETSY RAYMOND STEVENSON

Founder and Principal, RaymondStevenson Healthcare Communications (RSHC) >>>

ABOUT RSHC
Building Healthy Relationships

Expert and creative communications services for the pharmaceutical and biotechnology industries. >>>

PROFESSIONAL SOURCES

PR Week Healthcare . prweek
PRSA (Public Relations Society of America) . prsa
Healthcare Businesswomen's Association . hba
Bulldog Reporter The Daily Dog . dailydog
RSHC copyright © 2009